About Insys Therapeutics
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: INSY
- Previous Close: $12.80
- 50 Day Moving Average: $10.39
- 200 Day Moving Average: $12.11
- 52-Week Range: $8.70 - $21.22
- Trailing P/E Ratio: 40.89
- Foreward P/E Ratio: 40.00
- P/E Growth: 0.55
- Market Cap: $918.66M
- Outstanding Shares: 71,770,000
- Beta: 0.26
- Net Margins: 8.71%
- Return on Equity: 9.39%
- Return on Assets: 7.09%
Companies Related to Insys Therapeutics:
- Current Ratio: 3.07%
- Quick Ratio: 2.70%
What is Insys Therapeutics' stock symbol?
Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."
When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?
Insys Therapeutics's stock split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were payable to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.
Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2017?
7 equities research analysts have issued 1 year price targets for Insys Therapeutics' shares. Their forecasts range from $16.00 to $30.00. On average, they expect Insys Therapeutics' stock price to reach $21.67 in the next twelve months.
When will Insys Therapeutics announce their earnings?
Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Insys Therapeutics stock?
Insys Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (8.46%), Folger Hill Asset Management LP (1.72%), Dimensional Fund Advisors LP (0.80%), State Street Corp (0.63%), Credit Agricole S A (0.43%) and FMR LLC (0.36%). Company insiders that own Insys Therapeutics stock include Brian Tambi, Daniel Brennan, Darryl S Baker, Fosse Franc Del, John N Kapoor Trust Dated Sept, Michael L Babich, Patrick Fourteau, Steven J Meyer and Theodore H Stanley.
Who sold Insys Therapeutics stock? Who is selling Insys Therapeutics stock?
Insys Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, FMR LLC, Folger Hill Asset Management LP, Two Sigma Investments LP, Federated Investors Inc. PA, GSA Capital Partners LLP, Renaissance Technologies LLC and Dimensional Fund Advisors LP. Company insiders that have sold Insys Therapeutics stock in the last year include Daniel Brennan, Patrick Fourteau and Theodore H Stanley.
Who bought Insys Therapeutics stock? Who is buying Insys Therapeutics stock?
Insys Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Credit Agricole S A, A.R.T. Advisors LLC, Tudor Investment Corp Et Al and Menora Mivtachim Holdings LTD.. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept and Steven J Meyer.
How do I buy Insys Therapeutics stock?
Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Insys Therapeutics stock cost?
One share of Insys Therapeutics stock can currently be purchased for approximately $12.80.